SBIR PHASE I AWARD

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$650,021.00
Award Year:
2011
Program:
SBIR
Phase:
Phase I
Contract:
N43CO110055
Award Id:
n/a
Agency Tracking Number:
N43CO110055
Solicitation Year:
2011
Solicitation Topic Code:
NCI
Solicitation Number:
n/a
Small Business Information
2545 GOLDEN BEAR DR STE 110, CARROLLTON, TX, 75006-2474
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
610368925
Principal Investigator:
NANCY TEMPLETON
(214) 220-4304
NTEMPLETON@GRADALISINC.COM
Business Contact:
NANCY TEMPLETON
(214) 220-4304
NTEMPLETON@GRADALISINC.COM
Research Institution:
Stub




Abstract
The objective of this proposal is to define the in vivo effectiveness of a melanoma-targeted nanoparticle for systemic therapeutic delivery. The approach is to utilize a clinically experienced fusogenic bilamellar invaginated vesicle nanoparticle (BIV NP)with a manually extruded DOTAP:cholesterol formulation for the systemic delivery of DNA and RNAi expression plasmids. This will involve the preclinical validation of two recent technological advances: reversible masking and tumor-specific ligand decoration. Reversible masking is a non-toxic alternative to pegylation and involves transient coating with small, uncharged, lipids to bypass non-targeted organs and re-exposure of charge at the target cells for enhanced transfection. Further, the BIV NP will be decorated with low mw, non-immunogenic beta-turn "semi-peptidic" small molecules that mimic secondary structure motifs found at hot-spots in protein-ligand interactions. The small molecule candidate is selected by screening with melanoma cell lines and patient primary cultures for enhanced transgene expression. The project will include: 1) prioritization of low mw ligands that promote BIV-delivered transgene expression; 2) demonstration in nu/nu-hu melanoma xenograft models of the enhanced expression and anti-tumor activity of BIV NPs with pre-established anti-oncogene activities (bi-shSTMN1 payload); and 3) implementation of a GMP manufacturing process for the formulated melanoma-targeted, reversibly-masked bi-shSTMN1-BIV product. These activities will pave the way for future safety/toxicology studies and early phase clinical trials.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government